Patient Square Capital LP
In its 13F for Q4 2024 (holdings as of December 31, 2024, filed February 14, 2025), Patient Square Capital LP reported 20 stock positions worth $267.4 million. Its top holding was Roivant Sciences (ROIV) at 55.2% of the portfolio, followed by Liquidia (LQDA, 8.2%) and Insmed (INSM, 7.9%). Compared with Q3 2024, it opened 9 new positions, added to 9 and reduced 2. The biggest buy was Insmed (INSM, shares +79%) and the biggest sale Liquidia (LQDA, shares −74%).
- Most Recent 13F
- Q2 2026
- Location
- MENLO PARK, CA
- CIK
- 0001819257
- Portfolio Value
- $267.4M (Q4 2024)
- SEC Filing
- 0000950123-25-002377 ↗ filed Feb 14, 2025
Holdings Value
Holdings 20 stocks · $267.4M
| ROIV Roivant Sciences Ltd. | 55.22% | 12,480,000 | $147.6M | Add +2.1% |
| LQDA Liquidia Corp. | 8.18% | 1,860,371 | $21.9M | Reduce -74.1% |
| INSM Insmed Inc. | 7.93% | 307,167 | $21.2M | Add +78.9% |
| CGEM Cullinan Therapeutics Inc. | 4.00% | 878,897 | $10.7M | Add +6.6% |
| EYPT Eyepoint Inc. | 3.93% | 1,410,331 | $10.5M | Add +3.5% |
| NRIX Nurix Therapeutics Inc. | 3.14% | 446,296 | $8.4M | Add +37.0% |
| ITCI Intra-Cellular Therapies Inc. | 2.25% | 71,990 | $6.0M | New |
| ELVN Enliven Therapeutics Inc. | 1.89% | 224,038 | $5.0M | Add +147.4% |
| GERN Geron Corp. | 1.75% | 1,321,268 | $4.7M | New |
| OCUL Ocular Therapeutix Inc. | 1.50% | 470,919 | $4.0M | Add +100.0% |
| AGIO Agios Pharmaceuticals Inc. | 1.50% | 121,732 | $4.0M | New |
| PHVS Pharvaris NV | 1.49% | 207,603 | $4.0M | Reduce -14.3% |
| IRON Disc Medicine Inc. | 1.34% | 56,400 | $3.6M | New |
| SWTX Springworks Therapeutics Inc. | 1.26% | 93,137 | $3.4M | New |
| ALLO Allogene Therapeutics Inc. | 1.19% | 1,489,909 | $3.2M | New |
| MIRM Mirum Pharmaceuticals Inc. | 1.00% | 64,900 | $2.7M | New |
| NTLA Intellia Therapeutics Inc. | 0.94% | 215,981 | $2.5M | Add +68.0% |
| ARVN Arvinas Inc. | 0.62% | 86,627 | $1.7M | New |
| SRRK Scholar Rock Holding Corp. | 0.52% | 32,000 | $1.4M | New |
| ATXS Astria Therapeutics Inc. | 0.35% | 105,057 | $939K | Add +166.5% |
Portfolio Sells Q3 2024 → Q4 2024
Portfolio Buys Q3 2024 → Q4 2024
| INSM Insmed Inc. | Add +78.9% | 7.93% | +3.28 |
| ROIV Roivant Sciences Ltd. | Add +2.1% | 55.22% | +2.84 |
| ITCI Intra-Cellular Therapies Inc. | New | 2.25% | +2.25 |
| GERN Geron Corp. | New | 1.75% | +1.75 |
| AGIO Agios Pharmaceuticals Inc. | New | 1.50% | +1.50 |
| IRON Disc Medicine Inc. | New | 1.34% | +1.34 |
| SWTX Springworks Therapeutics Inc. | New | 1.26% | +1.26 |
| ALLO Allogene Therapeutics Inc. | New | 1.19% | +1.19 |
| ELVN Enliven Therapeutics Inc. | Add +147.4% | 1.89% | +1.03 |
| MIRM Mirum Pharmaceuticals Inc. | New | 1.00% | +1.00 |
| OCUL Ocular Therapeutix Inc. | Add +100.0% | 1.50% | +0.74 |
| ARVN Arvinas Inc. | New | 0.62% | +0.62 |
| SRRK Scholar Rock Holding Corp. | New | 0.52% | +0.52 |
| NRIX Nurix Therapeutics Inc. | Add +37.0% | 3.14% | +0.43 |
| ATXS Astria Therapeutics Inc. | Add +166.5% | 0.35% | +0.19 |
| NTLA Intellia Therapeutics Inc. | Add +68.0% | 0.94% | −0.04 |
| EYPT Eyepoint Inc. | Add +3.5% | 3.93% | −0.11 |
| CGEM Cullinan Therapeutics Inc. | Add +6.6% | 4.00% | −1.12 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 23 | $645.5M | ROIV, RVMD, MIRM, ABVX, ONC |
| Q1 2026 | 29 | $563.6M | ROIV, ARGX, INSM, ONC, COGT |
| Q4 2025 | 28 | $467.1M | ROIV, INSM, MIRM, ARGX, ONC |
| Q3 2025 | 24 | $373.9M | ROIV, INSM, EYPT, ABVX, CDTX |
| Q2 2025 | 19 | $277.4M | ROIV, INSM, ARGX, EYPT, LQDA |
| Q1 2025 | 19 | $241.7M | ROIV, INSM, LQDA, EYPT, OCUL |
| Q4 2024 | 20 | $267.4M | ROIV, LQDA, INSM, CGEM, EYPT |
| Q3 2024 | 11 | $269.4M | ROIV, LQDA, CGEM, INSM, EYPT |
| Q2 2024 | 2 | $215.4M | ROIV, LQDA |
| Q1 2024 | 2 | $234.8M | ROIV, LQDA |